New biotechnology trends will not only influence the delivery and cost of healthcare, but are also expected to impact agriculture, commercial and industrial production. The annual J. P. Morgan Healthcare Conference from January 10-13 will bring together established industry leaders, emerging fast growth companies, innovative technology creators and globally minded service providers in San Francisco, CA with a total number of attendees expected to be over 8500. There will be 350 private and public companies presenting and pitching what’s new and different about their ideas to over 3,500 investors. There will be multiple half-hour public company presentation tracks.
The stock market crash of 2008 set the clock back in terms of investments, IPOs, entrepreneurship, R&D activities, and hiring. The biotech industry is now leading the way out of the economic slump with higher fundraising activity, more investments, and uptick in hiring. And yet, continuing economic volatility, healthcare reform, barriers to early-stage financing of innovation, rising healthcare costs, rising costs of drug development, aging population, increasingly hostile reimbursement environment are all pointing to uncertainty regarding the health of the biotech industry. So what type of biotech companies are attracting VC investments? Which technologies are grabbing their attention? How will the evolving structure of biotech M&As influence corporate partnerships, licensing deals, alternative financing and developmental strategies? The buzz coming out of the J. P. Morgan conference will point to answers to these and other related challenges and questions facing the biotech and pharmaceutical industries. Stay tuned to hear more about how the bio pharma companies are repositioning themselves and to hear more about the breakthroughs in science and technology that will be expected to influence the future of this industry sector.